查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447730

多形性胶质母细胞瘤治疗市场评估：按药物、疗法、最终用户和地区划分的机会和预测（2017-2031）

Glioblastoma Multiforme Treatment Market Assessment, By Drug, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5个工作天内

价格

2024年至2031年的预测期内，全球多形性胶质母细胞瘤治疗市场规模预计将以8.78%的复合年增长率增长，从2023年的29.1亿美元增长至57.1亿美元。 近年来，市场经历了显着成长，预计未来将保持强劲成长速度。

全球多形性胶质母细胞瘤治疗市场的成长是由于多形性胶质母细胞瘤在人群中患病率的不断增加、创新疗法的发展以及製药和药物发现行业的显着增长所推动的。其驱动因素有以下几个：包括： 政府措施、主要参与者增加投资开发优质高效的药物、支持性监管框架以及医疗器材製造商和製药公司之间的合资企业也有望进一步加速细胞肿瘤治疗的成长市场。

多形性胶质母细胞瘤盛行率增加

由于全球多形性胶质母细胞瘤病例数量不断增加，对多形性胶质母细胞瘤治疗的需求显着增加。 胶质母细胞瘤是一种快速转移并引起进一步併发症的癌症，使其成为全球癌症患者死亡的主要原因之一。 根据德州大学西南医学中心发表的一篇论文，全球每年诊断出超过 30 万例胶质母细胞瘤。 据说它是成人中最常见的原发性恶性脑瘤。 胶质母细胞瘤患者的平均存活时间为 15-18 个月，这进一步凸显了研发的必要性，以实现有效的治疗过程，从而提高患者的存活率。

整合人工智慧加速药物开发进程

人工智慧在製药公司中的应用因其巨大的潜力而变得越来越重要，包括药物开发过程中合成路线的分析和生成以及临床试验设计的优化。 多形性胶质母细胞瘤治疗市场新兴市场的领导者正在利用人工智慧和机器学习等最新先进技术来增强其研发流程，以在癌症治疗过程中创造更有效率、更有益的治疗方法。我们不断致力于带来治癒方法。

放射治疗作为一种治疗方法在市场上占据主导地位

在多形性胶质母细胞瘤患者的各种治疗方式中，放射治疗的应用明显增加。 放射治疗在多形性胶质母细胞瘤的治疗中发挥重要作用。 手术切除肿瘤后，建议单独进行放射治疗或与化疗联合治疗，以杀死任何剩余的癌细胞并防止未来的癌细胞生长。 多家公司参与开发创新疗法，以提高放射治疗的效率。 例如，2023年12月，Shuttle Pharmaceuticals Holdings, Inc.宣布已向FDA提交研究性新药（IND）申请，以支持下一阶段临床试验中罗□酮尿甘的开发。 Lopidoxuridine 是一种放射增敏剂，用于多形性胶质母细胞瘤的放射治疗。 这种创新方法旨在提高癌症存活率并延长患者的生命。

本报告调查了全球多形性胶质母细胞瘤治疗市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构和市场成长。它总结了影响因素分析、案例研究、竞争格局和主要公司概况。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球多形性胶质母细胞瘤治疗市场展望

  • 市场规模/预测
  • 透过药物
    • 替莫唑胺
    • 洛莫司汀
    • 贝伐珠单抗
    • 其他
  • 依治疗方法
    • 手术
    • 放射治疗
    • 化疗
    • 标靶治疗
    • 其他
  • 按最终用户
    • 医院
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球多形性胶质母细胞瘤治疗市场展望：按地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 透过药物
  • 依治疗方法
  • 按最终用户
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Azurity Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co
  • Eli Lilly and Company
  • Lantern Pharma Inc.
  • Karyopharm Therapeutics Inc.

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11137

Global glioblastoma multiforme treatment market is projected to witness a CAGR of 8.78% during the forecast period 2024-2031, growing from USD 2.91 billion in 2023 to USD 5.71 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in global glioblastoma multiforme treatment market is being driven by several factors such as increase in the prevalence of glioblastoma multiforme among the population, the development of innovative therapeutical drugs, and tremendous growth in the pharmaceutical and drug discovery industry. Government initiatives, growing investments by key market players to develop quality and efficient drugs, along with a supportive regulatory framework and collaborative ventures between medical device manufacturers and pharmaceutical companies will further promote the growth of the global glioblastoma multiforme treatment market.

The global glioblastoma multiforme treatment market is significantly undergoing robust growth due to the increasing prevalence of glioblastoma multiforme worldwide. As glioblastoma multiforme is a fast-growing tumor, it is highly essential to get treatment as early as possible to develop any fatal condition. Glioblastoma multiforme treatment methods such as surgery, chemotherapy, and radiation therapy play a crucial role in increasing the life expectancy of the patients. With the growing cases of glioblastoma, there is an increased demand for glioblastoma multiforme treatments due to which many leading players are continuously involved in launching innovative and efficient therapeutical drugs in their cancer treatment product portfolio, which is further propelling the growth of the global glioblastoma multiforme treatment market.

Government initiatives such as granting funds are being initiated to improve research and development in the market to improve medical facilities and provide efficient treatment to the patients. Product launches by key market players, along with increased collaboration activities such as mergers and acquisitions, partnership agreements, and new distribution agreements, drive the global glioblastoma multiforme treatment market. Moreover, several market leaders are undergoing extensive research and development in the market to launch innovative and efficient drugs. Celldex Therapeutics that develops targeted immunotherapy and biologics for the treatment of different types of cancers, announced that its latest drug "Varlilumab" is under clinical trial phase II and is most likely to progress into phase III.

Increasing Prevalence of Glioblastoma Multiforme

The demand for glioblastoma multiforme treatment is increasing significantly due to the rising number of glioblastoma multiforme cases worldwide. Glioblastoma is a leading cause of death among the cancer patients globally, as it is a type of cancer that spreads faster, leading to further health complications. According to an article published in "UT Southwestern Medical Center", globally, more than 300,000 cases of glioblastoma are diagnosed every year. It states that it is the most common primary malignant brain cancer in the adult population. The survival time for glioblastoma patients is only 15 to 18 months on an average, which further emphasizes the need for research and development to bring efficient treatment process that can increase the survival rate of the patients.

Integration of AI For Expediting Drug Development Process

The use of artificial intelligence in pharmaceutical companies is becoming more significant, due to its huge potential to analyze and generate synthesis pathways during the drug development process, as well as optimize clinical trial designs. Leading players in the glioblastoma multiforme treatment market are continuously involved in using the latest advanced technologies such as artificial intelligence and machine learning to enhance the research and development process, to bring more efficient therapeutic drugs, that can be beneficial in the treatment process of cancer.

For instance, in October 2023, Lantern Pharma Inc., using its AI-based platform, "RADR", announced that its latest innovative drug "LP-184" for the treatment of glioblastoma was published in the American Association for Cancer Research Journal. It states that LP-184 is a unique small molecule that has highly efficient CNS penetration and low nanomolar activity. With the help of its AI platform RADR, LP-184 is developed in such a way that it can repair damaged DNA. Moreover, it has been proven to be effective for patients with temozolomide resistance.

Radiation Therapy Dominates the Market in Terms of Treatment Methods

Among the different treatment methods for glioblastoma multiforme patients, the application of radiation therapy is increasing significantly. Radiation therapy plays a crucial part in the treatment of glioblastoma multiforme. After the surgical removal of a tumor, radiation therapy alone or in combination with chemotherapy is recommended to kill the remaining cancer cells and limit the growth of cancer cells in the future. Several companies are involved in developing innovative therapeutics to make radiation therapies more efficient. For instance, in December 2023 Shuttle Pharmaceuticals Holdings, Inc. announced application submission of an investigational new drug (IND) to the FDA, to support the company in the development of Ropidoxuridine in the next phase of the clinical trial. Ropidoxuridine is a radiation sensitizer, that is used in radiation therapy to treat glioblastoma multiforme. The innovative approach aims to increase cancer survival rates and prolong a patient's life.

Hospitals Hold a Major Share in Glioblastoma Multiforme Treatment Market

Among the end-user segment, hospitals account for the highest market share in the global glioblastoma multiforme treatment market. The increasing global population and rising number of hospitals are expected to cater to the demands and the dominance of the segment in the market. Glioblastoma multiform is an aggressive brain tumor that requires different treatments such as surgery, chemotherapy, and radiation therapy. Hospitals provide all these facilities, along with highly qualified surgeons and healthcare providers, which helps smoothen a patient's journey throughout the entire pathway from diagnosis to follow up and assessment. As the prevalence of cancer such as glioblastoma multiforme is increasing, the demand for hospitals in developed as well as developing countries are increasing, due to which countries are increasing the number of hospitals with advanced diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and more hospitals are under construction. Increased availability of a variety of treatment facilities in the healthcare setting, along with increased trust among the population regarding the reliability and quality of healthcare facilities provided in the hospitals is further driving the growth of hospital segment in the overall market.

North America Holds Significant Market Share

North America dominates global glioblastoma multiforme treatment market, due to its well-developed and highly efficient healthcare infrastructure and availability of the latest and advanced surgical techniques and therapeutical drugs for the treatment of glioblastoma multiforme. The growing prevalence of glioblastoma multiforme among the United States population is the prime factor, that is driving the growth of this market.

For instance, according to the "National Brain Tumor Society", in the United States, more than 10,000 individuals are affected by glioblastoma multiforme every year and it is estimated that out of all primary malignant brain tumors, 50.1% account for glioblastoma multiforme. The increasing prevalence requires efficient treatment such as surgeries, chemotherapy, and radiation therapy to increase the life span of the patients affected by this disease. Due to this, the demand for glioblastoma multiforme treatment is increasing in North America. Additionally, increased research and development in the market, along with the presence of key market players such as Amgen Inc and Merck & Co. further accelerate the demand for the global glioblastoma multiforme treatment market in the region.

Future Market Scenario (2024 - 2031F)

The global glioblastoma multiforme treatment market is expected to grow in the future, primarily due to increasing prevalence of glioblastoma multiforme worldwide. As the prevalence is increasing, pharmaceutical companies are constantly involved in extensive research and development of innovative therapeutical drugs for the treatment of the disease, along with mergers and acquisitions activities to enhance their product portfolio and expand their global market.

Additionally, the growth of the pharmaceutical industry, increased investments by organizations and government, frequent product launches, and increased FDA approvals by the regulatory bodies further lead to the growth of the global glioblastoma multiforme treatment market. For instance, in January 2024, Roche announced that its latest drug "Atezolizumab" is under clinical trial phase II and is most likely to get the FDA approval soon. The drug is expected to provide efficient treatment to the patients suffering from glioblastoma multiforme. These frequent product launches and favorable regulatory frameworks are further expected to escalate the growth of the market in the forecast period.

Key Players Landscape and Outlook

In the glioblastoma multiforme treatment market, pharmaceutical firms and biotechnological companies are consistently forming strategic partnerships and distribution agreements to enhance their productivity and global business. These collaboration activities play a crucial role in propelling the global glioblastoma multiforme treatment market's expansion. The strategic partnerships agreements, enable firms to gain in-depth insights into the market, strategically use each other's resources, markets, and technologies, and invest in research and development activities to bring innovative drug discovers and technological advancements in the treatment methods. Distribution agreements allow companies to expand their market presence globally. These collaborative initiatives promote innovation and expertise in product development, which improves patient health outcomes and contributes to the enduring and robust growth of the global glioblastoma multiforme treatment market.

For instance, in September 2023, Double Bond Pharmaceutical International AB, which is a pharmaceutical company that develops therapeutical drugs against cancer, announced its collaboration with Vivo Biopharma LLC, which is a subsidiary of Sauvie Inc. The collaboration will allow asset purchase and transition agreements for DBP's SI-053, which is a locally acting formulation of temozolomide, developed for the treatment of glioblastoma. As this latest drug has the potential to increase survival rate in patients suffering from glioblastoma, it is expected that the agreement will provide quality and advanced treatment to cancer patients and will support in elevating the market globally.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Drug
    • 4.2.1.Temozolomide
    • 4.2.2.Lomustine
    • 4.2.3.Bevacizumab
    • 4.2.4.Others
  • 4.3.By Treatment
    • 4.3.1.Surgery
    • 4.3.2.Radiation
    • 4.3.3.Chemotherapy
    • 4.3.4.Targeted Therapy
    • 4.3.5.Others
  • 4.4.By End-user
    • 4.4.1.Hospital
    • 4.4.2.Ambulatory Surgical Centers
    • 4.4.3.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Drug
      • 5.1.2.1.Temozolomide
      • 5.1.2.2.Lomustine
      • 5.1.2.3.Bevacizumab
      • 5.1.2.4.Others
    • 5.1.3.By Treatment
      • 5.1.3.1.Surgery
      • 5.1.3.2.Radiation
      • 5.1.3.3.Chemotherapy
      • 5.1.3.4.Targeted Therapy
      • 5.1.3.5.Others
    • 5.1.4.By End-user
      • 5.1.4.1.Hospital
      • 5.1.4.2.Ambulatory Surgical Centers
      • 5.1.4.3.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Drug
      • 5.1.5.2.1.Temozolomide
      • 5.1.5.2.2.Lomustine
      • 5.1.5.2.3.Bevacizumab
      • 5.1.5.2.4.Others
      • 5.1.5.3.By Treatment
      • 5.1.5.3.1.Surgery
      • 5.1.5.3.2.Radiation
      • 5.1.5.3.3.Chemotherapy
      • 5.1.5.3.4.Targeted Therapy
      • 5.1.5.3.5.Others
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospital
      • 5.1.5.4.2.Ambulatory Surgical Centers
      • 5.1.5.4.3.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Drug
  • 6.2.By Treatment
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.F. Hoffmann-La Roche Ltd
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Amgen Inc.
  • 13.3.Merck & Co., Inc.
  • 13.4.Pfizer Inc.
  • 13.5.Sun Pharmaceutical Industries Limited
  • 13.6.Azurity Pharmaceuticals, Inc.
  • 13.7.Bristol-Myers Squibb Co
  • 13.8.Eli Lilly and Company
  • 13.9.Lantern Pharma Inc.
  • 13.10.Karyopharm Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 4.Global Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 5.Global Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Glioblastoma Multiforme Treatment Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 10.North America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 11.North America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 16.United States Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 17.United States Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 21.Canada Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 22.Canada Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 26.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 27.Mexico Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 31.Europe Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 32.Europe Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 37.Germany Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 38.Germany Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 42.France Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 43.France Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 47.Italy Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 48.Italy Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 52.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 53.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 57.Russia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 58.Russia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 62.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 63.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 67.Spain Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 68.Spain Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 72.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 73.Turkey Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 77.Poland Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 78.Poland Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 82.South America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 83.South America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 88.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 89.Brazil Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 93.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 94.Argentina Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 98.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 99.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 101.India Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 104.India Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 105.India Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 109.China Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 110.China Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 114.Japan Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 115.Japan Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 119.Australia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 120.Australia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 124.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 125.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 129.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 130.South Korea Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 134.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 135.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 139.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 140.Philippines Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 144.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 145.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 150.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 151.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 155.UAE Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 156.UAE Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 160.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 161.South Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023